柔肝灵颗粒治疗偿期乙型肝炎肝硬化的临床研究.pdfVIP

中文摘要 目的：观察柔肝灵颗粒治疗气虚血瘀湿阻型代偿期乙型肝炎肝硬化的临床疗效，为 广泛应用于临床提供依据。 方法：临床选取符合纳入标准的代偿期乙型肝炎肝硬化中医辨证为气虚血瘀湿阻型 患者85 例，随机分为两组，治疗组患者(43例，治疗期间3 例脱落)服用柔肝灵颗 粒，对照组（42 例，治疗期间2 例脱落）服用复方鳖甲软肝片，两组中患者凡乙肝 病毒载量达到抗病毒适应症则应用阿德福韦酯胶囊针对病原学治疗，两组疗程为一 年，观察两组患者治疗前后的临床症状和体征变化，肝功变化及肝纤维化指标改变、 胃镜结果、上腹部B 超等。 结果：两组治疗后统计分析，治疗组总有效率为 85%,与对照组比较无显著性差异 (P0.05)；治疗组患者症状和体征都有明显的好转；两组患者治疗后肝功ALT、AST、 TBIL 均显著降低,但治疗组ALT、AST 较对照组统计有显著性差异(P0.05)；治疗后， 治疗组与对照组肝纤维化指标都显著下降，但两组结果比较统计有显著性差异 (P0.05)，治疗组明显优于对照组。B 超、胃镜结果显示，两组治疗后均比治疗前 明显改善(P0.05)，但两组间治疗后差异无统计学意义(P0.05)。 结论：对于气虚血瘀湿阻型代偿期乙型肝炎肝硬化患者，柔肝灵颗粒治疗代偿期肝 硬化的疗效强于复方鳖甲软肝片组。同时柔肝灵颗粒对于肝损伤具有一定的保护作 用，对于临床症状、体征的改善作用显著。 关键词:慢性乙型肝炎；代偿期肝硬化；柔肝灵颗粒；复方鳖甲软肝片；临床研究。 Clinical Study on Hepatocirrhosis in Chronic Hepatitis B Treated with Rouganling Keli Abstract Objective: I observed the curative effect of the Rouganling Keli in treating chronic hepatitis B with Qi deficiency blood stagnancy and damp retention hepatocirrhosis in order to provide the basis for the widely application in clinic treatment. Methods:Eighty-five patients of chronic hepatitis B with Qi deficiency blood stagnancy and damp retention hepatocirrhosis were randomly separated into the treated group(43 cases,3 cases were quit in the course) and the control group(42 cases,2 cases were quit in the course) which were treated with the Rouganling Keli,FFBJRGP respectively,with one year time,to observe the items of physical signs, clinical symptoms, hepatic function, indicators of liver fibrosis , gastroscopy and B-type ultrasonic of upper abdomen etc. All patients in both groups of hepatitis B viral load is applied to anti-viral indications capsule adefovir dipivoxil treatment for the pathogen. Result: The total curative rate in the treated group was 85% after treatment as the results showed,and the clinical effect of the treated group had no distinct statistical difference with the control group (P0.05)